Eyestem Announces completion of Phase one of its RPE cell therapy with promising efficacy and safety outcomes Learn More
Eyestem announces interim safety and efficacy data from ongoing Phase I trial using Eyecyte-RPE for the treatment of Geographic Atrophy patients, in an International Conference “The Future is Here II, Exploring New Frontiers of Ocular Research”, organized by LV Prasad Eye Institute, Hyderabad b/w Jan 9-12. Learn More
Eyestem receives positive recommendation from the Drug Safety Monitoring Board(DSMB) for the first set of patient injections for its pioneering Dry AMD treatment Learn More
Eyestem files for IND approval for its product to treat Geographic Atrophy, the largest cause of incurable blindness in the world for people over 50 Learn More
Eyestem announces US operations with appointment of Ravi Achar and engagement of Stradling advisors Learn More
